Compare Citius Pharmaceuticals Inc (CTXR) vs Lockheed Martin Corporation (LMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Lockheed Martin Corporation — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Lockheed Martin Corporation trades at $508.29 (market cap $117.22B). The key difference: Lockheed Martin Corporation is far larger — about 8606.5× Citius Pharmaceuticals Inc's market cap, and Lockheed Martin Corporation pays a 2.72% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Lockheed Martin Corporation for 86 Days on average.
| CTXR | LMT | |
|---|---|---|
Market Cap | $13.62M | $117.22B |
Volume | 132,438 | 1,101,121 |
Sector | Health | Industrials |
52-Week High | $1.82 | $676.70 |
52-Week Low | $0.48 | $439.19 |
Typical Hold Time | 16 Days | 86 Days |
Enterprise Value | $3.79M | $133.96B |
Dividend Yield | — | 2.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Lockheed Martin (LMT) trades at $499.22, down 2.14% over the past day, amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 18.73 and net income margin of 8.16%, though recent quarters saw mixed earnings results. Revenue growth is steady, reaching $75.05B in 2025, and the company maintains a robust dividend history, recently declaring a $3.45 payout. Analyst consensus remains bullish with a $635.33 price target, supported by ongoing defense spending and strategic initiatives like AI integration and Skunk Works innovation.
Outlook for LMT is positive due to solid defense contracts and technological advancements, but risks include fixed-price contract volatility and competitive pressures. The stock offers value with a below-sector P/E and high institutional confidence, though investors should monitor execution on earnings targets and macroeconomic impacts on defense budgets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →
